We are live on ! Find out more
ALBO

Albireo Pharma Inc
ALBO

Delisted

ALBO was delisted on the 2nd of March, 2023.

Back to rankings

30 hedge funds and large institutions have $81.8M invested in Albireo Pharma Inc in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 3

125% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 4

50% more capital invested

Capital invested by funds: $54.4M → $81.8M (+$27.3M)

36% more funds holding

Funds holding: 22 → 30 (+8)

Holders
30
Holders Change
+8
Holders Change %
+36.36%
% of All Funds
0.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
9
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$12M
2
AG
Artal Group
Luxembourg
+$7.61M
3
SAM
Sectoral Asset Management
Quebec, Canada
+$2.15M
4
Millennium Management
Millennium Management
New York
+$467K
5
AAP
Ardsley Advisory Partners
Connecticut
+$287K

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.91M
2
SFM
Sphera Funds Management
Israel
-$1.85M
3
Deutsche Bank
Deutsche Bank
Germany
-$1.43M
4
Renaissance Technologies
Renaissance Technologies
New York
-$375K
5
JMH
J.M. Hartwell
New York
-$147K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$33.8M +$12M +475,000 +56%
TGHSA
2
TPG Group Holdings (SBS) Advisors
Texas
$19.9M – – –
AG
3
Artal Group
Luxembourg
$7.68M +$7.61M +300,000 New
SAM
4
Sectoral Asset Management
Quebec, Canada
$6.22M +$2.15M +84,776 +54%
BBA
5
Baker Bros. Advisors
New York
$5.12M – – –
Renaissance Technologies
6
Renaissance Technologies
New York
$3.09M -$375K -14,800 -11%
Millennium Management
7
Millennium Management
New York
$1.19M +$467K +18,425 +65%
SFM
8
Sphera Funds Management
Israel
$907K -$1.85M -73,095 -67%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$815K – – –
Vanguard Group
10
Vanguard Group
Pennsylvania
$794K +$26.8K +1,056 +4%
BlackRock
11
BlackRock
New York
$316K +$34.9K +1,375 +13%
AAP
12
Ardsley Advisory Partners
Connecticut
$289K +$287K +11,300 New
Northern Trust
13
Northern Trust
Illinois
$252K +$249K +9,834 New
Morgan Stanley
14
Morgan Stanley
New York
$244K +$230K +9,065 +1,984%
JMH
15
J.M. Hartwell
New York
$241K -$147K -5,800 -38%
UBS Group
16
UBS Group
Switzerland
$234K +$232K +9,141 New
Bank of New York Mellon
17
Bank of New York Mellon
New York
$216K +$214K +8,438 New
Barclays
18
Barclays
United Kingdom
$172K +$170K +6,700 New
Wells Fargo
19
Wells Fargo
California
$162K +$119K +4,688 +282%
CIBC Private Wealth Group
20
CIBC Private Wealth Group
Georgia
$51K +$50.7K +2,000 New
PCM
21
Prelude Capital Management
New York
$51K +$50.7K +2,000 New
Manulife (Manufacturers Life Insurance)
22
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$9K +$101 +4 +1%
Macquarie Group
23
Macquarie Group
Australia
$8K +$7.61K +300 New
TDC
24
Thompson Davis & Co
Virginia
$6K +$5.58K +220 New
TRCT
25
Tower Research Capital (TRC)
New York
$2K +$583 +23 +55%
1
2

ALBO Hedge Fund Activity: Q4 2017 in Review

30 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q4 2017, worth a combined $81.8M — up 50% from $54.4M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ALBO positions and 3 closed out — a net gain of 8 holders — while 9 added to existing stakes and 4 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $12M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $3.91M sold.

  • 30 institutional investors held Albireo Pharma Inc (ALBO) as of Q4 2017, up from 22 in Q3 2017.
  • Funds reported $81.8M of Albireo Pharma Inc stock for Q4 2017, up 50% quarter-over-quarter.
  • 11 funds opened new Albireo Pharma Inc positions in Q4 2017 and 3 closed out, a net change of +8 holders.
  • The largest Albireo Pharma Inc buyer in Q4 2017 was Perceptive Advisors, an estimated $12M added.
  • The largest Albireo Pharma Inc seller in Q4 2017 was Point72 Asset Management, an estimated $3.91M sold.

Based on aggregated 13F filings for Q4 2017.